Cover Image
市場調查報告書

血脂異常症:開發平台分析

Hyperlipidemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213125
出版日期 內容資訊 英文 209 Pages
訂單完成後即時交付
價格
Back to Top
血脂異常症:開發平台分析 Hyperlipidemia - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 209 Pages
簡介

血脂異常症,是特徵為血流中的脂質過剩的疾病的混合群。可觀察到皮膚和肌腱的脂肪沉著、疼痛、肥大、內臟器官(肝臟、脾臟、胰臟等)腫大、心臟和腦的血管閉塞等症狀。原因為年齡,性別,停經後,緊張狀態,酒精成癮(酒精中毒)等。治療包含投藥(Statin等)、飲食療法、生活習慣的變更等。

本報告提供血脂異常症的治療藥的開發情形的調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

血脂異常症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

各調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

各調查中的產品:各大學/研究機關

開發治療藥的企業

  • Acasti Pharma Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arbutus Biopharma Corporation
  • Arisaph Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • BASF SE
  • BCWorld Pharm Co. Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cardax Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • CJ HealthCare Corp.
  • CymaBay Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Esperion Therapeutics, Inc.
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • 興和
  • LG Life Science LTD.
  • Lotus Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pharmena SA
  • Prometheon Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Sancilio & Company, Inc.
  • Thetis Pharmaceuticals LLC
  • Yuhan Corporation
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (amlodipine besylate + atorvastatin calcium + valsartan)
  • (amlodipine besylate + rosuvastatin calcium + valsartan)
  • (atorvastatin calcium + losartan potassium)
  • (atorvastatin calcium + metformin hydrochloride) XR
  • (candesartan + rosuvastatin calcium)
  • (gemigliptin + rosuvastatin calcium)
  • (metformin hydrochloride SR + rosuvastatin calcium)
  • AEM-28
  • AEM-2802
  • AEM-2814
  • ALN-AC3
  • ALN-ANG
  • ARI-3037MO
  • AS-1708727
  • BCWPC-001
  • bempedoic acid
  • bezafibrate ER
  • BH-03004
  • BioE-1115
  • bococizumab
  • BSN-272
  • CAT-2000 Series
  • CAT-2003
  • CDX-085
  • centatin
  • DS-8312
  • DWJ-1330
  • DWJ-1351
  • etanercept biosimilar
  • evolocumab
  • gemcabene calcium
  • HOB-071
  • HU-012
  • IBI-306
  • icosabutate
  • ISIS-APOCIIILRx
  • JLP-1302
  • JLP-1401
  • K-312
  • leucine + niacin
  • MAT-9001
  • MBX-8025
  • NKPL-66
  • 血脂異常症、動脈粥狀硬化性心血管疾病用核苷酸
  • 歐米加-3-羧酸
  • PF-06427878
  • PF-06815345
  • pitavastatin CR
  • 血脂異常症 用HMG-CoA 還原酶抑制蛋白
  • saroglitazar
  • SC-401
  • 血脂異常症用小分子
  • 高甘油三酯血症症用小分子
  • 第二型糖尿病、血脂異常症用小分子
  • 代謝障礙用 TRIP-Br2 阻礙小分子
  • 血脂異常症、高甘油三酯血症症用小分子
  • 心血管/消化器官/代謝障礙、感染疾病用合成肽
  • TKM-HTG
  • TKMApoC-3
  • TP-101
  • TRIA-662
  • volanesorsen sodium
  • YH-22189

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8344IDB

Summary

Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H2 2016', provides an overview of the Hyperlipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
  • The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperlipidemia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperlipidemia - Overview
    • Pipeline Products for Hyperlipidemia - Comparative Analysis
  • Hyperlipidemia - Therapeutics under Development by Companies
  • Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes
  • Hyperlipidemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hyperlipidemia - Products under Development by Companies
  • Hyperlipidemia - Products under Investigation by Universities/Institutes
  • Hyperlipidemia - Companies Involved in Therapeutics Development
    • Acasti Pharma Inc.
    • Akcea Therapeutics Inc
    • Allergan Plc
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Arisaph Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • BASF SE
    • BCWorld Pharm Co. Ltd.
    • BioRestorative Therapies, Inc.
    • Cadila Pharmaceuticals Limited
    • Cardax Pharmaceuticals, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • CJ HealthCare Corp.
    • CymaBay Therapeutics, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Esperion Therapeutics, Inc.
    • Golden Biotechnology Corp.
    • HanAll Biopharma Co., Ltd.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Huons Co., Ltd.
    • Hyundai Pharmaceutical Co., Ltd.
    • Innovent Biologics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Kowa Company, Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • LG Life Science LTD.
    • LipimetiX Development Inc
    • Matinas BioPharma Holdings, Inc.
    • Pfizer Inc.
    • Pharmena SA
    • Protalix BioTherapeutics, Inc.
    • Regeneron Pharmaceuticals Inc
    • Sancilio & Company, Inc.
    • Yuhan Corporation
    • Zydus Cadila Healthcare Limited
  • Hyperlipidemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile
    • (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile
    • (atorvastatin calcium + losartan potassium) - Drug Profile
    • (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile
    • (ezetimibe + rosuvastatin calcium) - Drug Profile
    • (gemigliptin + rosuvastatin calcium) - Drug Profile
    • (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile
    • AC-261066 - Drug Profile
    • AEM-28 - Drug Profile
    • AEM-2802 - Drug Profile
    • AEM-2814 - Drug Profile
    • ALN-AC3 - Drug Profile
    • ALN-ANG - Drug Profile
    • antroquinonol - Drug Profile
    • ARI-3037MO - Drug Profile
    • BCWPC-001 - Drug Profile
    • bempedoic acid - Drug Profile
    • bezafibrate ER - Drug Profile
    • BH-03004 - Drug Profile
    • BioE-1115 - Drug Profile
    • bococizumab - Drug Profile
    • BSN-272 - Drug Profile
    • CAT-2000 Series - Drug Profile
    • CAT-2003 - Drug Profile
    • CDX-085 - Drug Profile
    • centatin - Drug Profile
    • DWJ-1351 - Drug Profile
    • etanercept biosimilar - Drug Profile
    • evolocumab - Drug Profile
    • gemcabene calcium - Drug Profile
    • HOB-071 - Drug Profile
    • HU-012 - Drug Profile
    • IBI-306 - Drug Profile
    • icosabutate - Drug Profile
    • IMMH-007 - Drug Profile
    • ISIS-APOCIIILRx - Drug Profile
    • JS-002 - Drug Profile
    • K-312 - Drug Profile
    • leucine + niacin - Drug Profile
    • LTPO-3FA - Drug Profile
    • MAT-9001 - Drug Profile
    • MBX-8025 - Drug Profile
    • MN-002 - Drug Profile
    • NKPL-66 - Drug Profile
    • Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile
    • omega-3-carboxylic acids - Drug Profile
    • PF-06427878 - Drug Profile
    • PF-06815345 - Drug Profile
    • Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile
    • REGN-1001 - Drug Profile
    • saroglitazar - Drug Profile
    • SC-401 - Drug Profile
    • Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile
    • Small Molecule for Hyperlipidemia - Drug Profile
    • Small Molecule for Hypertriglyceridaemia - Drug Profile
    • Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile
    • Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile
    • Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
    • TRIA-662 - Drug Profile
    • volanesorsen sodium - Drug Profile
    • YH-22189 - Drug Profile
  • Hyperlipidemia - Dormant Projects
  • Hyperlipidemia - Discontinued Products
  • Hyperlipidemia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperlipidemia, H2 2016
  • Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hyperlipidemia - Pipeline by Acasti Pharma Inc., H2 2016
  • Hyperlipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Hyperlipidemia - Pipeline by Allergan Plc, H2 2016
  • Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Amgen Inc., H2 2016
  • Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Hyperlipidemia - Pipeline by AstraZeneca Plc, H2 2016
  • Hyperlipidemia - Pipeline by BASF SE, H2 2016
  • Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
  • Hyperlipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016
  • Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
  • Hyperlipidemia - Pipeline by CJ HealthCare Corp., H2 2016
  • Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Golden Biotechnology Corp., H2 2016
  • Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Huons Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Kowa Company, Ltd., H2 2016
  • Hyperlipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Hyperlipidemia - Pipeline by LG Life Science LTD., H2 2016
  • Hyperlipidemia - Pipeline by LipimetiX Development Inc, H2 2016
  • Hyperlipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Hyperlipidemia - Pipeline by Pfizer Inc., H2 2016
  • Hyperlipidemia - Pipeline by Pharmena SA, H2 2016
  • Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H2 2016
  • Hyperlipidemia - Pipeline by Yuhan Corporation, H2 2016
  • Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hyperlipidemia - Dormant Projects, H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..1), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..2), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..3), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..4), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..5), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..6), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..7), H2 2016
  • Hyperlipidemia - Dormant Projects (Contd..8), H2 2016
  • Hyperlipidemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hyperlipidemia, H2 2016
  • Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top